Understanding HER2 positive Breast Cancer and its Treatment

HER2 positive breast cancers require treatment with specific targeted therapies of which there are several.

by Dr. C.H. Weaver M.D. updated 10/2019

HER2 (human epidermal growth factor 2) is a receptor on the surface of breast cells. When HER2 is "turned on" it causes the cells to grow and reproduce. Normal breast cells have 2 copies of the gene that makes HER2. In contrast to normal breast cells some have more than two HER2 genes and/or produce too much HER2. This results in more HER2 receptors on breast cells - a condition doctors refer to as "over expression" Over expression of HER2 leads to increased breast cell production or cancer.

Doctors can test for HER2 with two different tests.

  • IHC - measures the number of HER2 receptors on a scale of 1-3. 3 + means there are too many.
  • ISH - counts the number of HER2 genes.

HER2 + "positive" breast cancers can be treated with precision cancer medicines that target the HER2 receptor. Approximately 20-25% of breast cancers. These cancers are referred to as HER2-positive.

There are several precision cancer medicines that target HER2 and the use of these medications improves the outcomes of women with both early-stage and advanced HER2-positive breast cancer.

Herceptin (trastuzumab)

Next Generation anti HER2 Precision Cancer Medicines

What are the side effects of HER2 therapies?

Should all HER2 + breast cancers be treated?

  • All invasive and metastatic HER 2 positive breast cancers benefit from HER2 directed therapy. Even very small cancers appear to benefit. A U.S. study evaluated the records of 965 women with small cancers that had not been treated with HER2-targeted therapy or chemotherapy. By the end of five years, 6% of women with HER2-negative breast cancer had a recurrence compared with 23% of women with HER2-positive breast cancer.

What is the role of HER 2 in DCIS?

Compared with invasive breast cancer, DCIS more often expresses HER2, however current research does not support the use of human HER2 - directed therapy in DCIS.

References:

  1. https://www.nccn.org/patients/guidelines/breast-invasive/22/
  2. Roses RE, Paulson EC, Sharma A et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiology, Biomarkers & Prevention. 2009 18: 1386-1389.
  3. Gonzalez AM, Litton JK, Broglio KR et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. Journal of Clinical Oncology[early online publication]. November 2, 2009.
  4. Curigliano G, Viale G, Bagnardi V et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. Journal of Clinical Oncology [early online publication]. November 2, 2009.
  5. Burstein HJ, Winer EP. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. Journal of Clinical Oncology [early online publication]. November 2, 2009.​
  6. https://www.nccn.org/patients/guidelines/stage_iv_breast/30/
  7. NCCN Guidelines Version 3.2013 Ductal Carcinoma in Situ. <a href="http://www.nccn.org/professionals/physician\_gls/pdf/breast.pdf">http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf</a> (Accessed on August 07, 2013).
  8. Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992; 23:974.

Copyright © 2018 CancerConnect. All Rights Reserved.

Comments